Service de Biologie Medicale
Service de Biologie Medicale
Henn A.,groupe hospitalier Pitie Salpetriere |
Perignon A.,groupe hospitalier Pitie Salpetriere |
Monsel G.,groupe hospitalier Pitie Salpetriere |
Larreche S.,Service de biologie medicale |
And 2 more authors.
Journal of travel medicine | Year: 2016
BACKGROUND: Travel and aquatic activities are increasing in tropical regions. The risk and the spectrum of marine envenomation are unknown in travellers. This work aims to evaluate the prevalence and the characteristics of marine envenomations in returning travellers.METHODS: We retrospectively studied the medical charts of all returning travellers presenting with a health problem in a French tropical disease unit between 2008 and 2013, with focus on travellers complaining of marine envenomation. Characteristics of each type of envenomation are described.RESULTS: Of the 3315 travellers seen during the study period, 43 consulted for a presumed marine envenomation. Six patients were excluded, leaving 37 cases of confirmed marine envenomation. It corresponds to a prevalence of 1.1%. Sex ratio was balanced with 18 men and 19 women. Median age was 42 years (range 25-68 years). Median travel duration was 14 days (range: 6-62 days). The main travel destination was Southeast Asia in 10 cases, followed by islands of East Africa in seven cases. Median elapsed time between envenomation and consultation was 14 days (range: 2-130 days). The purpose of travel was tourism in all cases. The main clinical aspects were oedema, sting marks, cellulitis and flagellations. Eleven cases were presumably caused by corals, 10 by stonefish, 8 by jellyfish, 2 by weever fish, 2 by starfish, 2 by stingray, 1 by lionfish and 1 by sea anemone.CONCLUSION: Prevalence of marine envenomation is low in returning travellers. They are mostly caused by corals, stonefish and jellyfish. © International Society of Travel Medicine, 2016. All rights reserved. For permissions, please e-mail: firstname.lastname@example.org.
El Khattabi A.,Service de medecine interne |
Sekkach Y.,Service de medecine interne |
Seddik H.,Service dhepato gastro enterologie |
Zahid H.,Service de biologie medicale
Annales Pharmaceutiques Francaises | Year: 2011
Iron deficiency anemia as a hematologic complication of the antithyroid medication (ATS) that has not been already described in the literature. We report on two exceptional cases: the first case concerns a 24 years old man admitted for an anemic syndrome. He was treated with carbimazole for Graves' disease. The blood count showed a non-regenerative microcytic anemia. Serum ferritin was severely decreased. The etiologic searching for bleeding, hemolysis, malabsorption or iron deficiency was negative. Treatment with iron salts was introduced without any real improvement. Given this situation, and given the negativity of the etiologic investigations, the decision to stop carbimazole was taken. Since that, the clinical and biological evolutions have been favorable. The second observation is much more original and concerns a 35 years old woman. The clinical, laboratory, etiological and treatment data are similar to those of the first observation. The evolution after withdrawal of carbimazole was favorable. The originality of this observation is that a reintroduction test of carbimazole was performed and allowed to reproduce the same haematological effects. These findings led us to hold the diagnosis of anaemia due to carbimazole. In this occasion, and in the light of the data in the literature, we underline the exceptional character of these two cases and we raise the possibility of an etiopathogenic link between administration of ATS and the occurrence of anaemia by iron deficiency. © 2011 Elsevier Masson SAS.
PubMed | Paris Center, Center Hospitalier Des Alpes, Montpellier University, University Paris - Sud and 3 more.
Type: Journal Article | Journal: Clinical and experimental immunology | Year: 2016
Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P=0003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.
Valdes V.,Service de neonatologie |
Legagneur H.,Service de biologie medicale |
Watrin V.,Service de biologie medicale |
Paris L.,Groupe hospitalier Pitie Salpetriere |
Hascoet J.-M.,Service de neonatologie
Archives de Pediatrie | Year: 2011
Reinfection with Toxoplasma gondii is exceptional but can lead to transmission to the fetus when it occurs during pregnancy. We present a case of congenital toxoplasmosis in a young baby born to an immunocompetent mother who had been immunized against toxoplasmosis before pregnancy. The presence of residual IgG-specific antibodies does not always mean an absolute protection against a new toxoplasma infection. During the pregnancy, the patient was advised to follow the hygienic and dietary preventive measures even though the previous test results were consistent with past toxoplasma infection. © 2011 Elsevier Masson SAS.
PubMed | groupe hospitalier Pitie Salpetriere, Service de biologie medicale and University Pierre and Marie Curie
Type: Journal Article | Journal: Journal of travel medicine | Year: 2016
Travel and aquatic activities are increasing in tropical regions. The risk and the spectrum of marine envenomation are unknown in travellers. This work aims to evaluate the prevalence and the characteristics of marine envenomations in returning travellers.We retrospectively studied the medical charts of all returning travellers presenting with a health problem in a French tropical disease unit between 2008 and 2013, with focus on travellers complaining of marine envenomation. Characteristics of each type of envenomation are described.Of the 3315 travellers seen during the study period, 43 consulted for a presumed marine envenomation. Six patients were excluded, leaving 37 cases of confirmed marine envenomation. It corresponds to a prevalence of 1.1%. Sex ratio was balanced with 18 men and 19 women. Median age was 42 years (range 25-68 years). Median travel duration was 14 days (range: 6-62 days). The main travel destination was Southeast Asia in 10 cases, followed by islands of East Africa in seven cases. Median elapsed time between envenomation and consultation was 14 days (range: 2-130 days). The purpose of travel was tourism in all cases. The main clinical aspects were oedema, sting marks, cellulitis and flagellations. Eleven cases were presumably caused by corals, 10 by stonefish, 8 by jellyfish, 2 by weever fish, 2 by starfish, 2 by stingray, 1 by lionfish and 1 by sea anemone.Prevalence of marine envenomation is low in returning travellers. They are mostly caused by corals, stonefish and jellyfish.
PubMed | Aix - Marseille University, Hopital Sainte Marguerite and Service de biologie medicale
Type: | Journal: Trials | Year: 2015
International recommendations in favor of screening for vaginal infection in pregnancy are based on heterogeneous criteria. In most developed countries, the diagnosis of bacterial vaginosis is only recommended for women with high-risk of preterm birth. The Nugent score is currently used, but molecular quantification tools have recently been reported with a high sensitivity and specificity. Their value for reducing preterm birth rates and related complications remains unexplored. This trial was designed to assess the cost-effectiveness of a systematic screen-and-treat program based on a point-of-care technique for rapid molecular diagnosis, immediately followed by an appropriate antibiotic treatment, to detect the presence of abnormal vaginal flora (specifically, Atopobium vaginae and Gardnerella vaginalis) before 20 weeks of gestation in pregnant women in France. We hypothesized that this program would translate into significant reductions in both the rate of preterm births and the medical costs associated with preterm birth.A multicenter, open-label randomized controlled trial (RCT) will be conducted in which 20 French obstetrics and gynecology centers will recruit eligible pregnant women at less than 20 weeks gestation with singleton pregnancy and with a low-risk factor for preterm birth. Interventions will include a) an experimental group that will receive a systematic rapid screen-and-treat program from a point-of-care analysis using a molecular quantification method and b) a control group that will receive usual care management. Randomization will be in a 1:1 allocation ratio. The primary endpoint that will be assessed over a period of 12 months will be the incremental cost-effectiveness ratio (ICER) expressed as cost per avoided preterm birth before 37 weeks. Secondary endpoints will include ICER per avoided preterm birth before 24, 28 and 32 weeks, obstetrical outcomes, neonatal outcomes, rates of treatment failure and recurrence episodes for positive women. Uncertainty surrounding these estimates will be addressed using nonparametric bootstrapping and represented using cost-effectiveness acceptability curves. A total of 6,800 pregnant women will be included.This appropriate randomized controlled design will provide insight into the cost-effectiveness and therefore the potential cost savings of a rapid screen-and-treat strategy for molecular abnormal vaginal flora in pregnant women. National and international recommendations could be updated based on the findings of this study.ClinicalTrials.gov: NCT02288832 (registration date: 30 October 2014); Eudract: 2014-001559-22.
Larreche S.,Service de Biologie Medicale |
Imbert P.,Service de Maternite pediatrie |
Mornand P.,Service de Maternite pediatrie |
Andriamanantena D.,Service des Maladies Infectieuses et Tropicales |
And 2 more authors.
Travel Medicine and Infectious Disease | Year: 2013
Snakebites are an infrequent but real risk for travelers. We report a case of envenomation by Bothrops atrox in a traveler to Manaus, Brazil. Rapid administration of specific antivenom prevented the expected systemic disorders. This case gives opportunity to review prevention and first aid measures of snakebites in travelers. © 2013 Elsevier Ltd. All rights reserved.
Merens A.,Service de Biologie Medicale |
Servonnet A.,Service de Biologie Medicale
Revue Francophone des Laboratoires | Year: 2010
Quinolones are potent antibacterial agents that specifically target bacterial DNA gyrase and topoisomerase IV. They are one of the largest classes of antimicrobial agents used wordwide, which explains the rise of the bacterial quinolone resistance. This resistance arises by mutations in the chromosomal genes of the quinolones targets, but also by changes in expression of efflux pumps and porins. More recently, plasmid mediated resistance mechanisms, involving three differents families of genes have been described in enterobacteria (target protection, quinolone acetylation and quinolone specific efflux). This article describes the different mechanisms of quinolone resistance, and the trends in fluoroquinolones resistance for the most common pathogens in human medicine (enterobacteria, Pseudomonas, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, M. tuberculosis). © 2010-Elsevier Masson SAS-Tous droits réserv́s.
Janvier F.,Service de biologie medicale |
Delacour H.,Service de biologie medicale |
Larreche S.,Service de biologie medicale |
Abdalla S.,Service de chirurgie viscerale et vasculaire |
And 2 more authors.
Pathologie Biologie | Year: 2013
Propionibacteria are organisms of low pathogenicity and only a minority of clinical Propionibacterium isolates is clinically significant. Herein, we report a rare case of Propionibacterium avidum abdominal wall and intra-peritoneal abscess that developed in 46-year-old woman after abdominal parietoplasty. © 2013 Elsevier Masson SAS.
Fecal carriage of third generation cephalosporins resistant Enterobacteteriaceae in asymptomatic young adults: Evolution between 1999 and 2009 [Portage digestif denté robacté ries résistantes aux céphalosporinesde troisiéme géné ration dans une population dadultes jeunes asymptomatiques :é volution entre 1999 et 2009]
Janvier F.,Service de biologie medicale |
Merens A.,Service de biologie medicale |
Delaune D.,Service de biologie medicale |
Soler C.,Service de biologie medicale |
Cavallo J.-D.,Service de biologie medicale
Pathologie Biologie | Year: 2011
Objectives: The aim of this work was to evaluate the fecal carriage of third generation cephalosporins resistant Enterobacteriaceae in nonhospitalized asymptomatic young adults. Methods: A total of 517 normal fecal samples were spread onto plates agar containing cefotaxime. Isolated strains were identified and studied with agar disk diffusion antibiogram, minimal inhibition concentration in liquid medium and phenotypic and molecular study. Data were compared with a previous study realised in the same conditions in 1999. Results: In 2009, the prevalence of cefotaxime resistant enterobacteria was 4.2%. Of these 22 Enterobacteriaceae, 11 harboured overexpressed cephalosporinase and 11 produced extended-spectrum-betalactamase (ESBL). Among ESBL, six E. coli produced CTX-M from group 1 (n=6), group 2 (n=1), group 9 (n=2), one E. coli produced SHV-12 and one Klebsiella pneumoniae produced CTX-M from group 1. All ESBL were multiresistant. In 1999, all the CTX resistant isolates recovered produced a cephalosporinase and no ESBL was found. Conclusions: This study highlights the increasing prevalence of fecal carriage of ESBL-producing enterobacteria in asymptomatic young patients in the community (0% in 1999 versus 2.1% in 2009; P< 0.001). E. Coli with CTX-M from group 1 was the most frequent ESBL identified, while fecal carriage of Enterobacteteriaceae overproducing cephalosporinase was similar (2.1%). © 2010 Elsevier Masson SAS.